Sause W T, Pajak T F, Noyes R D, Dobelbower R, Fischbach J, Doggett S, Mohiuddin M
LDS Hospital, Radiation Therapy Department, Salt Lake City, UT 84143.
Ann Surg. 1994 Nov;220(5):668-75. doi: 10.1097/00000658-199411000-00011.
Patients with operable colorectal cancer in the ascending colon, descending colon, and rectum were randomized to 500 cGy before definitive surgery. Patients with stage A and B1 lesions received no further treatment. All patients with stage B2, B3, C1, C2, and C3 received a minimum of 4500 cGy postoperatively.
Three hundred fifty-three patients were registered for the study. Three hundred one patients were available for analyses. Follow-up was a minimum of 5 years on all study patients. The majority of patients had rectal cancer. Complications of treatment were acceptable. Two hundred thirty-one patients had stage B2, B3, C1, C2, or C3 tumors. Estimated 5-year rates for no preoperative therapy versus preoperative therapy were as follows: local recurrence 29% versus 26%; metastasis 41% versus 43%; and survival 54% versus 54%. No statistical benefit was observed for preoperative treatment.
In a prospective randomized trial designed to test the value of low-dose preoperative irradiation followed by surgery and postoperative irradiation, the authors were unable to observe any benefit to low-dose preoperative therapy in patients with unfavorable stages.
将升结肠、降结肠和直肠可手术切除的结直肠癌患者随机分为两组,一组在根治性手术前接受500厘戈瑞(cGy)照射。A期和B1期病变患者不再接受进一步治疗。所有B2期、B3期、C1期、C2期和C3期患者术后至少接受4500厘戈瑞照射。
353例患者登记参加本研究。301例患者可进行分析。所有研究患者的随访时间至少为5年。大多数患者患有直肠癌。治疗并发症可以接受。231例患者患有B2期、B3期、C1期、C2期或C3期肿瘤。术前未治疗与术前治疗的估计5年发生率如下:局部复发分别为29%和26%;转移分别为41%和43%;生存率分别为54%和54%。未观察到术前治疗有统计学意义的益处。
在一项旨在测试低剂量术前照射继以手术和术后照射价值的前瞻性随机试验中,作者未能观察到低剂量术前治疗对预后不良分期患者有任何益处。